Poseida’s P-PSMA-101 Demonstrates Encouraging Efficacy in mCRPC; Upcoming Milestones for Poseida’s Allogeneic Platform; Poseida Seeking to Partner Their Emerging Technologies; Poseida’s R&D Day Summary
On Wednesday, February 23, Poseida Therapeutics held an R&D day (press release / presentation) highlighting the potential of their non-viral piggyBac gene delivery system for generating novel cell therapies. Moreover, management noted anticipated milestones for their allogeneic CAR-T platform. Below, Celltelligence provides insights on how Poseida’s allogeneic improvements could significantly decrease manufacturing costs, while discussing Poseida’s development of CAR-T therapies from different cell sources.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.